ICU Medical reported second quarter 2026 GAAP revenue of $551.7 million and adjusted diluted earnings per share of $2.37, exceeding prior-year results. The company significantly raised its full-year fiscal 2026 guidance, increasing the estimated GAAP net income range to $73–$83 million ($2.89–$3.29 per diluted share) and Adjusted EBITDA to $415–$435 million. These updates reflect strong performance in Infusion Systems and Consumables, partially offset by the May 2025 divestiture of the IV Solutions business. ICU Medical operates in the medical device industry, developing and manufacturing infusion systems, consumables, and critical care products.